Yubo International Biotech Limited (YBGJ)
USD 0.09
(-0.22%)
USD 0.09
(-0.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -1.17 Million USD | 22.6% |
| 2021 | -1.52 Million USD | -117.75% |
| 2020 | -698.73 Thousand USD | -1355.7% |
| 2019 | -48 Thousand USD | 17.24% |
| 2018 | -58 Thousand USD | 61.07% |
| 2017 | -149 Thousand USD | -136.51% |
| 2016 | -63 Thousand USD | -8.62% |
| 2015 | -58 Thousand USD | -5.45% |
| 2014 | -55 Thousand USD | 8.33% |
| 2013 | -60 Thousand USD | -27.66% |
| 2012 | -47 Thousand USD | 41.25% |
| 2011 | -80 Thousand USD | -26.98% |
| 2010 | -63 Thousand USD | 50.78% |
| 2009 | -128 Thousand USD | -60.0% |
| 2008 | -80 Thousand USD | 29.82% |
| 2007 | -114 Thousand USD | -26.67% |
| 2006 | -90 Thousand USD | 99.91% |
| 2005 | -100.99 Million USD | -50650.75% |
| 2004 | -199 Thousand USD | 93.39% |
| 2003 | -3.01 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -314.97 Thousand USD | -374.17% |
| 2023 Q2 | -348.95 Thousand USD | -10.79% |
| 2022 Q4 | 114.88 Thousand USD | 149.31% |
| 2022 Q3 | -232.99 Thousand USD | 52.08% |
| 2022 FY | - USD | 22.6% |
| 2022 Q1 | -573.35 Thousand USD | -49.94% |
| 2022 Q2 | -486.21 Thousand USD | 15.2% |
| 2021 Q1 | -433.64 Thousand USD | -51.22% |
| 2021 Q2 | -364.47 Thousand USD | 15.95% |
| 2021 Q3 | -340.96 Thousand USD | 6.45% |
| 2021 Q4 | -382.38 Thousand USD | -12.15% |
| 2021 FY | - USD | -117.75% |
| 2020 Q4 | -286.77 Thousand USD | 1.21% |
| 2020 FY | - USD | -1355.7% |
| 2020 Q3 | -290.29 Thousand USD | -871.38% |
| 2020 Q2 | -29.88 Thousand USD | 78.51% |
| 2020 Q1 | -139.07 Thousand USD | -1638.48% |
| 2019 FY | - USD | 17.24% |
| 2019 Q4 | -8000.00 USD | 0.0% |
| 2019 Q1 | -8000.00 USD | -14.29% |
| 2019 Q2 | - USD | 100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q4 | -7000.00 USD | 41.67% |
| 2018 FY | - USD | 61.07% |
| 2018 Q3 | -12 Thousand USD | 0.0% |
| 2018 Q1 | 8000.00 USD | 136.36% |
| 2018 Q2 | - USD | -100.0% |
| 2017 Q2 | - USD | 100.0% |
| 2017 Q3 | -22 Thousand USD | 0.0% |
| 2017 FY | - USD | -136.51% |
| 2017 Q1 | -96 Thousand USD | 0.0% |
| 2017 Q4 | -22 Thousand USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | -13 Thousand USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | - USD | -8.62% |
| 2015 Q1 | -11 Thousand USD | 35.29% |
| 2015 FY | - USD | -5.45% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | -14 Thousand USD | 0.0% |
| 2014 FY | - USD | 8.33% |
| 2014 Q4 | -17 Thousand USD | -21.43% |
| 2014 Q3 | -14 Thousand USD | 0.0% |
| 2013 Q1 | -14 Thousand USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | -27.66% |
| 2012 FY | - USD | 41.25% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | -9000.00 USD | 30.77% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | -26.98% |
| 2011 Q1 | -11 Thousand USD | 15.38% |
| 2011 Q4 | -13 Thousand USD | 0.0% |
| 2010 Q4 | -13 Thousand USD | 66.67% |
| 2010 Q1 | -20 Thousand USD | -42.86% |
| 2010 FY | - USD | 50.78% |
| 2010 Q3 | -39 Thousand USD | 0.0% |
| 2009 Q1 | -15 Thousand USD | 0.0% |
| 2009 Q4 | -14 Thousand USD | 0.0% |
| 2009 FY | - USD | -60.0% |
| 2008 FY | - USD | 29.82% |
| 2008 Q1 | 76 Thousand USD | 0.0% |
| 2007 Q1 | -5000.00 USD | 0.0% |
| 2007 FY | - USD | -26.67% |
| 2006 Q1 | -30 Thousand USD | 0.0% |
| 2006 FY | - USD | 99.91% |
| 2005 Q1 | -100.86 Million USD | 0.0% |
| 2005 FY | - USD | -50650.75% |
| 2004 FY | - USD | 93.39% |
| 2004 Q1 | 15 Thousand USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | -69 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | -22.172% |
| Ansell Limited | 209.86 Million USD | 100.561% |
| Ansell Limited | 206.3 Million USD | 100.571% |
| BG Medicine, Inc. | - USD | Infinity% |
| Biotage AB (publ) | 42.83 Million USD | 102.749% |
| BioLife Sciences Inc. | - USD | Infinity% |
| CB Scientific, Inc. | -1.62 Million USD | 27.525% |
| Psykey, Inc. | -1.29 Million USD | 9.08% |
| ConvaTec Group Plc | 455.5 Million USD | 100.259% |
| ConvaTec Group Plc | 455.5 Million USD | 100.259% |
| Encision Inc. | -544.19 Thousand USD | -116.409% |
| Golden Valley Development, Inc | -141.81 Thousand USD | -730.468% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | -971.305% |
| Innovative MedTech Inc. | -7.67 Million USD | 84.653% |
| LifePoint, Inc. | -14.2 Million USD | 91.708% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 80.965% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | -262.365% |
| QuantRx Biomedical Corporation | - USD | Infinity% |
| Remedent, Inc. | -215.23 Thousand USD | -447.165% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | -190.225% |
| SmileDirectClub, Inc. | -186.13 Million USD | 99.367% |
| Sector 10, Inc. | - USD | Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.263% |
| SheerVision, Inc. | -110.53 Thousand USD | -965.48% |
| United Health Products, Inc. | -2.5 Million USD | 52.934% |
| Vasamed, Inc. | -4.57 Million USD | 74.255% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 47.907% |